Amdocs Limited (DOX)
Quantitative Summary
DeterministicAt 12.4x earnings — a 81% discount to the sector average of 65.0x — DOX is in the lower valuation range. Financial health is average: Piotroski 5/9, Altman Z 4.3.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of Amdocs Limited reveal a company generating capital at an 11.9% ROIC, which must be weighed against the cost of equity to determine true value creation potential. The DuPont decomposition highlights that the 16.3% return on equity is driven primarily by financial leverage (Equity Multiplier of 1.80x) and solid profitability margins rather than operational efficiency; specifically, while net margins hold steady at 12.5%, asset turnover has contracted to 0.73x, signaling reduced capital productivity relative to revenue base. Although the Piotroski F-Score of 5/9 indicates moderate financial health with no distress signals, a declining score would warrant closer scrutiny on balance sheet strength and profitability trends.
Valuation metrics present a stark divergence between current market pricing and intrinsic value estimates derived from cash flow models. Trading at a forward P/E of 12.4x, the stock is priced significantly below its sector average of 58.2x, suggesting the market has heavily penalized recent performance rather than reflecting long-term structural deterioration. This discount appears justified by the reported -9.4% year-over-year revenue contraction, which contrasts sharply with the DCF fair value estimate of $64 that implies a different growth trajectory and risk profile. The gap between current trading levels and the modeled fair value indicates that investors are pricing in persistent headwinds or higher perpetual discount rates than those used in the valuation framework.
Risk assessment data offers mixed signals regarding earnings quality and future volatility. A Beneish M-Score of -2.72 suggests low probability of financial manipulation, providing some confidence in reported figures despite the revenue decline. However, the combination of negative top-line growth and a leverage-dependent ROE structure introduces operational risks that may not be fully captured by static valuation multiples. The convergence of deteriorating turnover metrics with a deeply discounted multiple creates an asymmetric setup where downside protection is priced in, yet recovery potential depends entirely on reversing the revenue trajectory to restore asset efficiency.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 6% | 7.7% | 9.7% |
|---|---|---|---|
| 2% | $74 | $51 | $37 |
| 3% | $95 | $61 | $42 |
| 4% | $139 | $75 | $48 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=7.6%, terminal growth 3%. Fair value $61 (+0.0%). Not investment advice.
Valuation Context
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like VFMV or ONEV, the fund manager is mechanically forced to buy or sell DOX shares regardless of Amdocs Limited's individual fundamentals. We estimate $69M of passive capital is structurally linked to DOX through 7 tracked ETFs. Passive flows have a limited but growing influence on DOX's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 7 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in Amdocs Limited to visualize passive redemption contagion across ETFs and collateral stocks.
If Amdocs Limited (DOX) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ALTRIA GROUP INC (MO) as the most exposed collateral stock, sharing 3 ETFs with DOX. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 7 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
DOX Ownership Dynamics
ETFs with Highest DOX Exposure
Float lock-up computed from 7 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
DOX Capital Efficiency
How efficiently does Amdocs Limited convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
Amdocs Limited converts 69% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 4.2% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-04-28 | 81 | $64.71 | $5,241.51 |
| 2026-04-27 | 153,209 | $65.31 | $10.0M |
| 2026-04-22 | 7,243 | $66.37 | $480,717.91 |
| 2026-04-15 | 488 | $64.98 | $31,710.24 |
| 2026-04-06 | 1 | $66.43 | $66.43 |
| 2026-04-01 | 3 | $65.26 | $195.78 |
| 2026-03-23 | 15,282 | $64.83 | $990,732.06 |
| 2026-03-11 | 160 | $67.86 | $10,857.6 |
| 2026-03-02 | 494 | $69.80 | $34,481.2 |
| 2026-02-17 | 3,800 | $69.23 | $263,074 |
| 2026-01-16 | 67 | $84.29 | $5,647.43 |
| 2026-01-09 | 192 | $84.07 | $16,141.44 |
| 2026-01-07 | 100 | $81.92 | $8,192 |
| 2025-12-29 | 9 | $81.73 | $735.57 |
| 2025-12-26 | 2,193 | $81.35 | $178,400.55 |
| 2025-12-24 | 2,175 | $80.30 | $174,652.5 |
| 2025-12-22 | 1,471 | $80.48 | $118,386.08 |
| 2025-12-10 | 23 | $77.15 | $1,774.45 |
| 2025-12-09 | 15,420 | $77.00 | $1.2M |
| 2025-12-05 | 5,183 | $76.45 | $396,240.35 |
| 2025-12-03 | 133 | $74.95 | $9,968.35 |
| 2025-12-01 | 65 | $76.48 | $4,971.2 |
| 2025-11-25 | 68 | $75.37 | $5,125.16 |
| 2025-11-21 | 119 | $74.98 | $8,922.62 |
| 2025-11-19 | 58 | $76.02 | $4,409.16 |
| 2025-11-13 | 7,822 | $77.36 | $605,109.92 |
| 2025-11-12 | 135,358 | $83.96 | $11.4M |
| 2025-11-10 | 33 | $84.57 | $2,790.81 |
| 2025-11-05 | 1,317 | $83.49 | $109,956.33 |
| 2025-11-04 | 8,370 | $84.13 | $704,168.1 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare DOX to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.